Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NovaBay Pharmaceuticals (NBY) FCF Margin (2016 - 2025)

Historic FCF Margin for NovaBay Pharmaceuticals (NBY) over the last 16 years, with Q3 2025 value amounting to 353.17%.

  • NovaBay Pharmaceuticals' FCF Margin changed N/A to 353.17% in Q3 2025 from the same period last year, while for Sep 2025 it was 53.59%, marking a year-over-year increase of 503300.0%. This contributed to the annual value of 53.05% for FY2024, which is 121100.0% down from last year.
  • According to the latest figures from Q3 2025, NovaBay Pharmaceuticals' FCF Margin is 353.17%.
  • NovaBay Pharmaceuticals' FCF Margin's 5-year high stood at 6.48% during Q4 2024, with a 5-year trough of 353.17% in Q3 2025.
  • Over the past 5 years, NovaBay Pharmaceuticals' median FCF Margin value was 60.96% (recorded in 2022), while the average stood at 78.98%.
  • Per our database at Business Quant, NovaBay Pharmaceuticals' FCF Margin crashed by -671200bps in 2021 and then skyrocketed by 1031500bps in 2022.
  • Over the past 5 years, NovaBay Pharmaceuticals' FCF Margin (Quarter) stood at 136.34% in 2021, then surged by 76bps to 33.19% in 2022, then dropped by -4bps to 34.51% in 2023, then surged by 119bps to 6.48% in 2024, then tumbled by -5548bps to 353.17% in 2025.
  • Its last three reported values are 353.17% in Q3 2025, 6.48% for Q4 2024, and 58.33% during Q2 2024.